WEBSITE BSE:524711 NSE: VISTA PHARMA Inc. Year: 1991 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 11:06
No Notes Added Yet
1. Business Overview
Vista Pharmaceuticals Ltd. operates in the Pharmaceuticals & Drugs sector in India. As a pharmaceutical company, its core business typically involves the research, development, manufacturing, marketing, and distribution of various pharmaceutical products. These products can range from finished dosage formulations (pills, capsules, injectables, syrups) to active pharmaceutical ingredients (APIs). The company's business model involves developing or acquiring drug formulations, producing them in its manufacturing facilities, and then selling them through various channels, including domestic sales to hospitals, pharmacies, and institutions, and potentially exports to international markets. Revenue is generated primarily through the sale of these pharmaceutical products.
2. Key Segments / Revenue Mix
Specific details regarding Vista Pharmaceuticals Ltd.'s key business segments or revenue mix (e.g., breakdown by therapeutic area, domestic vs. international sales, formulations vs. APIs) are not available from the provided information. Generally, pharmaceutical companies may segment their revenue by therapeutic categories (e.g., cardiology, diabetes, anti-infectives), geographical regions, or product types.
3. Industry & Positioning
The Indian pharmaceutical industry is highly competitive and fragmented, characterized by a strong focus on generic drugs, cost-effective manufacturing, and an increasing presence in regulated global markets. India is a significant producer and exporter of generic medicines. Without specific market share data or a detailed product portfolio, Vista Pharmaceuticals Ltd.'s precise positioning relative to its peers is not discernible. It operates within this competitive landscape, likely alongside numerous other domestic and international players vying for market share in various therapeutic segments. Its positioning would depend on its specific product offerings, manufacturing capabilities, and market reach.
4. Competitive Advantage (Moat)
Specific competitive advantages or moats for Vista Pharmaceuticals Ltd. are not explicitly known. In the pharmaceutical industry, potential moats can include:
Cost-efficient Manufacturing: Ability to produce drugs at a lower cost, especially generics.
Regulatory Expertise: Strong track record in navigating complex regulatory pathways in domestic and international markets (e.g., US FDA, EU EMA).
Distribution Network: Extensive reach and efficient logistics for product distribution.
Strong R&D Pipeline: Development of differentiated or novel formulations.
Brand Equity: For specific products that have built trust and recognition among healthcare professionals and patients.
Scale: Large-scale manufacturing capabilities offering economies of scale.
Without further information, it is difficult to determine if Vista Pharmaceuticals Ltd. possesses any durable competitive advantages.
5. Growth Drivers
Key factors that could drive growth for a pharmaceutical company like Vista Pharmaceuticals Ltd. over the next 3-5 years include:
Growing Healthcare Expenditure: Increasing disposable incomes and government initiatives boosting healthcare spending in India.
Rising Disease Burden: Increasing prevalence of chronic and lifestyle diseases demanding more pharmaceutical interventions.
Generic Opportunities: Patent expiries of blockbuster drugs presenting opportunities for generic manufacturers.
Export Potential: Expansion into regulated markets (e.g., US, Europe) and emerging markets due to India's cost-effective manufacturing base.
Government Initiatives: Schemes like Ayushman Bharat increasing access to medicines.
New Product Launches: Introduction of new drugs or differentiated formulations.
6. Risks
Vista Pharmaceuticals Ltd., like other companies in the sector, faces several risks:
Intense Competition & Pricing Pressure: High competition, especially in the generics segment, can lead to price erosion and impact profitability.
Regulatory Scrutiny: Stringent and evolving regulations in India and international markets can lead to compliance costs, delays, or product recalls.
Raw Material Volatility: Fluctuations in the prices and availability of key raw materials can impact production costs and supply chains.
Foreign Exchange Fluctuations: For companies involved in exports or imports, currency volatility can affect revenues and costs.
Intellectual Property Challenges: Potential for patent litigations or challenges to product exclusivity.
Product Development & Commercialization Risks: Failure in R&D or challenges in successfully launching new products.
Environmental & Social Compliance: Increasing pressure for sustainable and ethical practices.
7. Management & Ownership
Information regarding the specific promoters, management quality, and detailed ownership structure of Vista Pharmaceuticals Ltd. is not available in the provided data. In India, many companies are promoter-led, where founding families or groups hold significant control and influence over strategic decisions.
8. Outlook
The outlook for Vista Pharmaceuticals Ltd. is influenced by the broader dynamics of the Indian pharmaceutical industry.
Bull Case: The company could benefit from strong underlying demand for pharmaceutical products, India's inherent advantages in cost-effective manufacturing, and potential expansion into new therapeutic areas or geographical markets. Effective product development, robust regulatory compliance, and a strong distribution network could enable sustainable growth.
Bear Case: The company faces significant headwinds from intense competition, ongoing pricing pressures, and stringent regulatory environments. Any failure in product quality, regulatory non-compliance, or inability to launch new, commercially viable products could negatively impact its performance and market position. Its ability to navigate these challenges and capitalize on industry growth will be crucial for its future performance. The specific trajectory of Vista Pharmaceuticals Ltd. will depend heavily on its internal strategies, operational execution, and financial health, which are not detailed in the available information.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹46 Cr.
Stock P/E -9.9
P/B 1.1
Current Price ₹7.5
Book Value ₹ 6.9
Face Value 2
52W High ₹12
Dividend Yield 0%
52W Low ₹ 5.7
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 3 | 2 | 3 | 2 | 2 | 3 | 3 | 2 | 1 | 2 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 4 | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 2 | 3 |
| Total Expenditure | 5 | 3 | 3 | 3 | 3 | 4 | 4 | 3 | 5 | 5 |
| Operating Profit | -1 | -2 | 0 | -1 | -1 | -1 | -1 | -1 | -3 | -3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -2 | -2 | -0 | -1 | -1 | -2 | -1 | -1 | -4 | -3 |
| Provision for Tax | 0 | -1 | -0 | -0 | -0 | -0 | 0 | -0 | -1 | -1 |
| Profit After Tax | -2 | -2 | 0 | -1 | -1 | -1 | -1 | -1 | -3 | -2 |
| Adjustments | 0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 | -0 | 0 |
| Profit After Adjustments | -2 | -2 | 0 | -1 | -1 | -1 | -1 | -1 | -3 | -2 |
| Adjusted Earnings Per Share | -0.5 | -0.3 | 0 | -0.1 | -0.2 | -0.2 | -0.2 | -0.2 | -0.4 | -0.4 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 14 | 15 | 24 | 29 | 31 | 23 | 1 | 0 | 1 | 10 | 10 | 8 |
| Other Income | 0 | 0 | 0 | 0 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 14 | 15 | 24 | 29 | 34 | 27 | 1 | 1 | 1 | 11 | 11 | 10 |
| Total Expenditure | 11 | 13 | 21 | 24 | 30 | 28 | 3 | 2 | 5 | 14 | 14 | 17 |
| Operating Profit | 3 | 3 | 3 | 6 | 4 | -1 | -2 | -1 | -4 | -3 | -4 | -8 |
| Interest | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 1 | 1 | 3 | 1 | -4 | -4 | -3 | -6 | -5 | -5 | -9 |
| Provision for Tax | -0 | 0 | -0 | 1 | 0 | -0 | -2 | -2 | -0 | -1 | -1 | -2 |
| Profit After Tax | 1 | 1 | 1 | 2 | 1 | -4 | -2 | -1 | -6 | -5 | -5 | -7 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 1 | 1 | 1 | 2 | 1 | -4 | -2 | -1 | -6 | -5 | -5 | -7 |
| Adjusted Earnings Per Share | 0.5 | 0.3 | 0.5 | 0.8 | 0.3 | -1.2 | -0.5 | -0.2 | -1.5 | -1 | -0.8 | -1.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | 0% | -15% | -3% |
| Operating Profit CAGR | 0% | 0% | 0% | NAN% |
| PAT CAGR | 0% | 0% | 0% | NAN% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -33% | -5% | -9% | 3% |
| ROE Average | -11% | -14% | -10% | -2% |
| ROCE Average | -9% | -9% | -7% | 1% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 10 | 11 | 17 | 32 | 36 | 30 | 33 | 35 | 37 | 40 | 45 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 8 | 6 | 6 | 6 | 6 | 9 | 7 | 5 | 3 | 2 |
| Other Non-Current Liabilities | 0 | 0 | -1 | -0 | -0 | -0 | 2 | -3 | -3 | -3 | -4 |
| Total Current Liabilities | 12 | 7 | 19 | 15 | 11 | 16 | 9 | 13 | 14 | 14 | 12 |
| Total Liabilities | 23 | 26 | 41 | 53 | 53 | 51 | 53 | 52 | 53 | 55 | 56 |
| Fixed Assets | 11 | 10 | 13 | 18 | 21 | 21 | 20 | 19 | 20 | 19 | 19 |
| Other Non-Current Assets | 0 | 0 | 2 | 7 | 9 | 9 | 17 | 9 | 11 | 22 | 22 |
| Total Current Assets | 12 | 16 | 26 | 28 | 23 | 21 | 15 | 24 | 22 | 13 | 15 |
| Total Assets | 23 | 26 | 41 | 53 | 53 | 51 | 53 | 52 | 53 | 55 | 56 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 6 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | -4 | -2 | 3 | -5 | 3 | 1 | -7 | -1 | -2 | -5 | -7 |
| Cash Flow from Investing Activities | -0 | -0 | -4 | -11 | -6 | -2 | -0 | -0 | -1 | -1 | -0 |
| Cash Flow from Financing Activities | 4 | 3 | 6 | 11 | 1 | 0 | 7 | 1 | 3 | 6 | 8 |
| Net Cash Inflow / Outflow | 0 | 0 | 5 | -4 | -1 | -1 | -0 | -0 | 0 | -0 | 1 |
| Closing Cash & Cash Equivalent | 0 | 0 | 6 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.54 | 0.31 | 0.47 | 0.75 | 0.31 | -1.21 | -0.55 | -0.24 | -1.51 | -0.96 | -0.76 |
| CEPS(Rs) | 0.96 | 0.72 | 0.85 | 1.21 | 0.76 | -0.77 | -0.35 | -0.07 | -1.34 | -0.8 | -0.64 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 4.17 | 4.48 | 6.25 | 9.02 | 10.97 | 9.76 | 8.93 | 9.64 | 8.13 | 7.56 | 7.38 |
| Core EBITDA Margin(%) | 19.69 | 16.89 | 12.64 | 18.47 | 3.98 | -21.08 | -136.58 | -321.16 | -430.09 | -34.5 | -39.96 |
| EBIT Margin(%) | 12.14 | 10.45 | 8.68 | 15.22 | 9.08 | -10.53 | -178.65 | -435.33 | -451.83 | -38.25 | -42.91 |
| Pre Tax Margin(%) | 9.14 | 5.45 | 5.06 | 9.78 | 3.69 | -17.29 | -300.96 | -663.36 | -585.46 | -50.33 | -52.51 |
| PAT Margin (%) | 9.91 | 5.03 | 5.16 | 7.56 | 3.02 | -16.16 | -158.61 | -225.19 | -564.11 | -43.86 | -46.14 |
| Cash Profit Margin (%) | 17.51 | 11.63 | 9.36 | 12.18 | 7.41 | -10.24 | -101.15 | -69.03 | -502.58 | -36.86 | -38.82 |
| ROA(%) | 7.39 | 3.15 | 3.7 | 4.67 | 1.78 | -7.11 | -3.89 | -1.7 | -10.73 | -8.35 | -8.41 |
| ROE(%) | 13.94 | 7.15 | 8.97 | 10.19 | 3.15 | -11.68 | -6.43 | -2.6 | -17.16 | -13.63 | -11.47 |
| ROCE(%) | 14.16 | 9.57 | 8.92 | 12.42 | 6.28 | -5.2 | -5.1 | -3.75 | -9.58 | -8.28 | -8.54 |
| Receivable days | 163.68 | 249.65 | 141.56 | 125.43 | 112.81 | 149.36 | 1794.1 | 5842.77 | 3948.36 | 273.88 | 137.33 |
| Inventory Days | 12.15 | 34.39 | 81.65 | 120.26 | 130.14 | 167.81 | 2790.39 | 8791.54 | 3091.84 | 256.57 | 271.84 |
| Payable days | 298.61 | 272.7 | 220.78 | 252.2 | 103.28 | 82.74 | 2566.27 | 5212.95 | 849.73 | 312.19 | 284.27 |
| PER(x) | 6.35 | 0 | 75.08 | 48.92 | 65.15 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0.83 | 0 | 5.64 | 4.07 | 1.84 | 0.54 | 1.01 | 0.96 | 1.03 | 1.41 | 1.46 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 3.43 | 0.81 | 4.1 | 4.02 | 2.3 | 1.38 | 34.61 | 117.6 | 41 | 5.65 | 7.22 |
| EV/Core EBITDA(x) | 17.39 | 4.75 | 31.87 | 20.26 | 17.08 | -29.85 | -28.56 | -42.12 | -10.51 | -18.08 | -20.3 |
| Net Sales Growth(%) | 65.59 | 11.88 | 57.23 | 19.58 | 7.45 | -26.76 | -94.44 | -68.84 | 154.36 | 924.99 | -2.07 |
| EBIT Growth(%) | 250.31 | -3.71 | 30.61 | 109.76 | -35.91 | -184.93 | 5.57 | 24.07 | -164 | 13.22 | -9.85 |
| PAT Growth(%) | 191.7 | -43.14 | 61.14 | 75.27 | -57.04 | -491.48 | 45.37 | 55.76 | -537.18 | 20.31 | -3.03 |
| EPS Growth(%) | 75.01 | -43.13 | 51.59 | 59.78 | -58.77 | -491.53 | 54.92 | 55.76 | -524.27 | 36.55 | 21.05 |
| Debt/Equity(x) | 0.39 | 0.7 | 0.68 | 0.42 | 0.34 | 0.52 | 0.33 | 0.35 | 0.33 | 0.22 | 0.16 |
| Current Ratio(x) | 0.98 | 2.26 | 1.35 | 1.83 | 2.14 | 1.33 | 1.65 | 1.86 | 1.58 | 0.92 | 1.19 |
| Quick Ratio(x) | 0.96 | 1.89 | 0.92 | 1.11 | 1.11 | 0.72 | 0.6 | 1.13 | 1.03 | 0.45 | 0.53 |
| Interest Cover(x) | 4.05 | 2.09 | 2.4 | 2.79 | 1.69 | -1.56 | -1.46 | -1.91 | -3.38 | -3.17 | -4.47 |
| Total Debt/Mcap(x) | 0.16 | 0 | 0.12 | 0.1 | 0.18 | 0.96 | 0.32 | 0.37 | 0.32 | 0.16 | 0.11 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 27.81 | 27.81 | 21.19 | 21.19 | 21.19 | 21.19 | 21.19 | 21.19 | 21.19 | 21.19 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Public | 72.16 | 72.16 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 3.38 | 3.38 | 4.85 | 4.85 | 4.85 | 4.85 | 4.85 | 4.85 | 4.85 | 4.85 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4.69 | 4.69 | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
